Back
medRxiv

Genetic architecture and polygenic prediction of self-reported response to selective serotonin reuptake inhibitors in individuals with depression: a genome-wide meta-analysis

Kamp M, Singh M, Hu K, et al. — medRxiv 2026 · November 2026
Relevance score
5/10
Disease / domain
Response to selective serotonin reuptake inhibitors in depression
Source
medRxiv
DOI 10.64898/2026.11.11.26367161

Gene–drug pair / mechanism

Polygenic architecture of self-reported SSRI response, with a sub-threshold signal on glutamate transport (SLC17A6) and GABAergic involvement

Summary

SSRIs are first-line treatment for depression, but response is highly variable and no robust genetic predictor is known. This genome-wide meta-analysis of self-reported SSRI response includes 62,879 individuals of European ancestry with depression (72.6% responders) across six cohorts. SNP-based heritability is modest (3.1%) and no variant reaches genome-wide significance; gene-set analyses implicate GABAergic and glutamatergic neurotransmission, with a sub-threshold signal for SLC17A6. A leave-one-out polygenic score is associated with response in independent cohorts (OR 1.05; 95% CI 1.02-1.08; p = 0.002). Polygenic scores for depression, ADHD, anxiety, PTSD, autism, addiction and schizophrenia are associated with poorer response, and the educational attainment score with better response.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

Preprint, not peer reviewed. An OR of 1.05 has no bearing on choosing an antidepressant for an individual patient, and response is patient-reported rather than clinician-assessed: the result stands as a biological lead (GABA, glutamate), not as a tool. The authors' case for self-report as a route to larger samples is the methodological contribution, to be judged against a GWAS that has not yet identified any variant.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 1/3Evidence 2/3Novelty 1/2Sample 1/1Publication 0/1

Clinical impact: 1/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 5/10

Keywords

SSRIdepressionpolygenic risk scorePRSGWAS
Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime